Clinical Trials Browser

Leukemia, Prolymphocytic, T-Cell × venetoclax × 90 days × Clear all

NCT07311746 2025-12-31

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

Phase 1/2 Not yet recruiting

LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell